Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
World game at war: why some European nations have threatened a World Cup boycott 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
EDEN PRAIRIE, Minn., April 12, 2018 -- CHF Solutions, Inc. (Nasdaq:CHFS) announced today its commercial expansion into the Hong Kong market through its Asia distributor, Transmedic. Further, Transmedic has confirmed its first commercial orders for both Singapore and Hong Kong.
"Our expansion into the Asian markets is a key factor in our commercialization strategy, and our distribution partner, Transmedic, has flawlessly initiated on executing that strategy,” commented John Erb, chairman and chief executive officer of CHF Solutions. “We believe the heart failure market for patients suffering from fluid overload remains largely untapped in Asia and that the Aquadex FlexFlow system provides a clinically proven alternative therapy option over pharmacotherapy.”
These commercial orders were for both Aquadex FlexFlow consoles and the corresponding disposable products.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
[email protected]
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
[email protected]
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
[email protected]
